Compare ASTE & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | AVXL |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 397.6M |
| IPO Year | N/A | N/A |
| Metric | ASTE | AVXL |
|---|---|---|
| Price | $44.99 | $3.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $41.00 | $22.00 |
| AVG Volume (30 Days) | 192.6K | ★ 2.8M |
| Earning Date | 11-05-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,368,800,000.00 | N/A |
| Revenue This Year | $8.19 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $21.63 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $29.65 | $2.86 |
| 52 Week High | $50.83 | $14.44 |
| Indicator | ASTE | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 34.82 |
| Support Level | $45.72 | $3.56 |
| Resistance Level | $47.56 | $4.88 |
| Average True Range (ATR) | 1.35 | 0.32 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 29.02 | 12.12 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.